qertsolutions.blogg.se

• #Kisqali side effect skin

Antibody-drug conjugatesĪn antibody-drug conjugate (ADC) is a monoclonal antibody linked to a chemotherapy drug. Margetuximab (Margenza): This HER2 monoclonal antibody can be used along with chemo to treat advanced breast cancer, typically after at least 2 other drugs that target HER2 have been tried. Trastuzumab, pertuzumab, and hyaluronidase injection (Phesgo): This is a combination of these drugs given as a subcutaneous (under the skin) shot over several minutes. Pertuzumab (Perjeta): This HER2 monoclonal antibody can be given with trastuzumab and chemo, either before or after surgery to treat early-stage breast cancer, or to treat advanced breast cancer. Trastuzumab and hyaluronidase injection (Herceptin Hylecta) is given as a subcutaneous (under the skin) shot over a few minutes. Herceptin was the original brand name for trastuzumab, but several similar versions (called biosimilars) are now available as well, including Ogivri, Herzuma, Ontruzant, Trazimera, and Kanjinti.

#Kisqali side effect skin

This drug can be given into a vein (IV) or as an injection under the skin (subcutaneous). For advanced breast cancer, treatment is often given for as long as the drug is helpful. When started before (neoadjuvant) or after (adjuvant) surgery to treat early breast cancer, this drug is usually given for 6 months to a year. This drug is often given with chemo, but it might also be used alone (especially if chemo alone has already been tried). Trastuzumab (Herceptin and other brand names): Trastuzumab can be used to treat both early-stage and advanced breast cancer. In this case, they attach to the HER2 protein on cancer cells, which can help stop the cells from growing. Monoclonal antibodies are man-made versions of immune system proteins (antibodies) that are designed to attach to a specific target. Different types of drugs have been developed that target the HER2 protein.

These cancers, known as HER2-positive breast cancers, tend to grow and spread more aggressively than HER2-negative breast cancers. Of breast cancers, the cancer cells make too much of a growth-promoting protein known as HER2.

Targeted therapy for HER2-positive breast cancer